Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Swashthik Plascon Limited specializes in producing a range of packaging solutions primarily for the consumer goods sector in India. The company differentiates itself through its innovative product designs and sustainable packaging materials, which are increasingly demanded by environmentally conscious consumers.
SPL generates revenue through the sale of various packaging products, leveraging its strong relationships with major FMCG companies. The company benefits from pricing power due to its focus on sustainable materials, which are gaining traction in the market, allowing for premium pricing.
Demand fluctuations in the FMCG sector, particularly in India
Raw material price volatility, especially for plastics and sustainable materials
Regulatory changes affecting packaging standards
Technological advancements in packaging solutions
Increasing regulatory pressures on plastic usage and waste management
Technological disruption from alternative packaging solutions
Intensifying competition from local and international packaging firms
Potential market share loss to companies with superior sustainable offerings
Moderate debt levels with a Debt/Equity ratio of 0.94, which may constrain financial flexibility
Free cash flow negative, indicating potential liquidity concerns
high - SPL's performance is closely tied to consumer spending trends and overall economic growth in India.
Higher interest rates could increase financing costs for SPL's capital expenditures, potentially impacting profitability and expansion plans.
minimal - The company does not heavily rely on credit for operations, given its current ratio of 2.08.
value - Investors may find SPL attractive due to its low valuation metrics (P/S of 0.3x, P/B of 0.4x) relative to peers.
moderate - The stock has shown significant price fluctuations, particularly with a 1-year return of -51.1%.